The data generated to day in PONV, CINV and xerostomia have been excellent; we look forward to continued success therefore. Dr Alex Pasteur of Fidelity Biosciences added, Significant numbers of post-surgical patients usually do not receive sufficient nausea and vomiting prophylaxis. APD421, Acacia Pharma's lead item, a D2/D3 antagonist, showed excellent efficacy in its Stage II trial, and had a very good safety profile. We believe that a drug with this novel system and displaying these characteristics can provide a significant contribution to the treatment of post-surgical patients. Dr Martin Edwards of Novo A/S stated, In addition to APD421, Acacia Pharma has generated excellent Phase II a proof-of-idea data on APD403 in CINV.Our experienced field-based representatives will continue steadily to deliver outstanding support on a wide range of products to physicians and specialists all over the world. And our effective global supply chain is recognized as a global leader broadly, with continuing excellence in quality and customer support. ‘Supporting the growth of this innovative market model is our strategically concentrated R&D engine, built on novel compounds in specialty and major care markets where there is usually significant unmet medical want, and fueled by approximately $1.7 billion in annual investment.